MIT uses AI to help RNA vaccines last a year at room temperature

MIT researchers used a machine-learning algorithm to find a formulation that kept RNA vaccine particles stable for up to a year at room temperature, or two months at nearly 37°C. In tests in mice, the stored vaccines produced immune responses comparable to a similar Moderna-style formulation, a result that could ease one of RNA vaccines’ most stubborn distribution problems.

MIT CSAIL Watch analysis

What happened

The team used the algorithm to predict combinations of excipients, the ingredients added to lipid nanoparticles that protect and deliver mRNA. It narrowed the search to a promising formulation in a few rounds of testing, work the researchers say took weeks rather than months.

The researchers tested the formulation with COVID-19 mRNA vaccines in mice after vacuum-drying and storing the particles. They also made solid microneedle patches carrying a SARS-CoV-2 antigen, which produced a similar immune response to injectable RNA vaccines in the reported tests. The findings were published in Nature Biotechnology, according to MIT News.

Why it matters

RNA vaccines usually need very cold storage, which complicates shipping and access in places without reliable cold chains. A formulation that tolerates ordinary room temperatures could make distribution simpler and may support delivery approaches such as microneedle patches.

The result is promising, not a ready-made human vaccine or proof that the formulation works for every mRNA medicine. The evidence described here is from laboratory and animal studies; clinical use still lies ahead.

Our read

This is a useful example of machine learning doing practical experimental-design work: narrowing a difficult search so researchers can spend fewer months testing combinations by hand. The attractive part is not an AI label on a vaccine, but the possibility of getting fragile medicines through a less elaborate cold chain.

What to watch

• Whether the formulation is tested in people and retains its stability and immune response.
• Whether the approach works for other mRNA payloads and vaccine formulations.
• Whether microneedle patches can be developed into a practical delivery option.

Discussion spark: If heat-stable RNA vaccines prove safe and effective in people, should funders prioritise simpler storage and distribution over newer delivery methods such as microneedle patches?

Independent WittyWires tracker for public updates about MIT CSAIL. Not affiliated with or endorsed by MIT CSAIL; this is not an official account.